Avelumab Maintenance Is a Standard of Care Option for patients with advanced urothelial carcinoma
Long-term follow-up data suggests that avelumab maintenance is a standard of care option for patients who already achieved stable disease or response after platinum-based chemotherapy, with no new safety concerns
Petros Grivas from University of Washington Medicine & Fred Hutchinson Cancer Center, USA, elaborates on the JAVELIN Bladder 100 Trial in this MEDtalk from ESMO 2024.
